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BACKGROUND: Aspirin reduces mortality for men and
women with coronary heart disease (CHD). Previous
research suggests women with acute coronary syn-
dromes receive less aggressive care, including less
frequent early administration of aspirin. The presence
of gender differences in aspirin use for secondary
prevention is less clear.
OBJECTIVE: To determine if a gender difference exists
in the use of aspirin for secondary prevention among
individuals with CHD.
DESIGN: We analyzed data from the nationally repre-
sentative 2000–2002 Medical Expenditure Panel Sur-
veys to determine the prevalence of regular aspirin use
among men and women with CHD.
PARTICIPANTS: Participants, 1,869, 40 years and
older who reported CHD or prior myocardial infarction.
RESULTS: Women were less likely than men to use
aspirin regularly (62.4% vs 75.6%, p <.001) even after
adjusting for demographic, socioeconomic and clinical
characteristics (adjusted OR=0.62, 95% CI, 0.48–0.79).
This difference narrowed but remained signiﬁcant when
the analysis was limited to those without self-reported
contraindications to aspirin (79.8% vs 86.4%, P = .002,
adjusted OR=0.68, 95% CI, 0.48–0.97). Women were
more likely than men to report contraindications (20.5%
vs12.5%,P < .001).Differencesinaspirinuseweregreater
between women and men with private health insurance
(61.8% vs 79.0%, P<.001, adjusted OR = 0.48, 95% CI,
0.35–0.67) than amongthose withpubliccoverage(62.5%
vs70.7%,P = .04, adjusted OR = 0.74, 95% CI, 0.50–1.11)
(P <.001forgender–insurance interaction).
CONCLUSION: We found a gender difference in aspirin use
among patients with CHD not fully explained by differences
in patient characteristics or reported contraindications.
These ﬁndings suggest a need for improved secondary
prevention of cardiovascular events for women with CHD.
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INTRODUCTION
Aspirin confers protection against myocardial infarction (MI),
stroke, and other vascular events and reduces mortality for
men and women with coronary heart disease (CHD).
1 Although
the utility of aspirin for the primary prevention of vascular
events in otherwise healthy women is unclear,
2–4 strong
evidence supports the beneﬁts of aspirin for women with
CHD.
1,5 American College of Cardiology (ACC)/American Heart
Association (AHA) guidelines therefore recommend daily aspi-
rin for all patients with atherosclerotic cardiovascular disease
unless contraindicated.
5,6
Gender differences in the management of acute coronary
syndromes, including the use of thrombolytics, angioplasty,
beta-blockers, and aspirin, are well documented.
7–13 Given
aspirin’s clear beneﬁts for both women and men with CHD,
gender differences in its use that persist beyond the inpatient
experience could additionally impact the health of women with
CHD on a population level. However, less is known about
gender differences in outpatient care of CHD in general,
14–17
and few studies have speciﬁcally assessed gender differences
in aspirin use among men and women with CHD.
18,19
Estimating aspirin use poses a special challenge. Aspirin’s
low cost, over-the-counter availability, and widely known bene-
ﬁts for patients with CHD distinguish it as a unique medication
whose patterns of use are difﬁcult to measure and may be less
subject to mechanisms proposed to explain gender disparities in
other medical treatments.
11,16,20 For example, differences in
prescription drug coverage are less likely to affect aspirin use.
Consequently, gender differences in aspirin use may not corre-
spond to those demonstrated for other aspects of care for CHD.
Most studies addressing gender differences in the outpa-
tient care of patients with CHD were limited to local popula-
tions or particular health systems
14,15,17,21,22 and others
lacked outpatient measures of aspirin use.
7,12,21 Two studies
utilized national data but relied on ambulatory visit documen-
tation that may not accurately measure aspirin use, and these
were estimated per visit reporting rates rather than population
prevalences.
18,19 As a result, estimates of aspirin use vary
widely, from 33%
19 to 83%
17 to 97%,
15 and the signiﬁcance of
gender differences in the general population of patients with
CHD remains unclear.
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55Therefore, to more clearly deﬁne population-level differences
in aspirin use between women and men with CHD and to
investigate patient characteristics that may contribute to or
modify such differences, we used data from a nationally
representative survey to compare self-reported aspirin use by
gender in adults with CHD.
SUBJECTS AND METHODS
Data Source
We analyzed data from the 2000, 2001, and 2002 Medical
Expenditure Panel Survey (MEPS), a survey sponsored by the
Agency for Healthcare Research and Quality and the National
Center for Health Statistics. MEPS is designed to provide
nationally representative estimates of health care use, expen-
ditures, sources of payment, and insurance coverage.
23,24
Starting in 2000, condition-speciﬁc questions were included
to assess whether care is consistent with practice guidelines.
25
Each panel of respondents is drawn from the previous year’s
National Health Interview Survey, and respondents are repeat-
edly interviewed in person 5 times over a 2 1/2-year period
using computer-assisted personal interviewing technology.
Response rates for the three survey years varied between
64.7% and 66.3%.
23 The MEPS survey design is complex,
involving multistage sampling and producing stratiﬁed and
clustered data. Information is provided to account for the
complex survey design, including weights to adjust for nonre-
sponse and disproportionate sampling. Each year of data
provides a representative sample of the U.S. civilian noninsti-
tutionalized population. MEPS has been used previously to
study various issues relating to women’s health, gender
disparities, and cardiovascular disease.
26–28 Because this
study used publicly available anonymous data, the Institu-
tional Review Board of Brigham and Women’s Hospital deemed
it exempt from review.
Study Population
Our study cohort included participants 40 years of age or older
at the time of the survey who reported a diagnosis of coronary
heart disease (CHD) or a previous heart attack or myocardial
infarction (MI). Individuals with missing values for demograph-
ic or clinical variables were excluded.
Study Variables
Aspirin use and covariates were ascertained from self-reports.
Participants or their proxies were asked two questions to
determine the presence of CHD: “Have you ever been told by
a doctor or other health professional that you had [coronary
heart disease],” or “[a heart attack, also called myocardial
infarction or MI]?” Those who replied yes to either of these
questions were asked, “Do you take aspirin everyday or every
other day?” Respondents with MI or CHD who did not report
regular aspirin use were asked, “Do you have a health problem
or condition that makes taking aspirin unsafe?” Those who
reported such a contraindication were speciﬁcally asked “Is
that problem stomach-related or something else?” Neither the
dose nor the duration of aspirin use was determined, and
speciﬁc contraindications were not characterized beyond
whether they were “stomach-related.”
Demographic and socioeconomic covariates included age (at
the time of the interview), gender, health insurance status
(private insurance, public with no private insurance, or un-
insured), education (<high school education, high school
graduate, or >high school education), poverty category (income
0–124%, 125–199%, 200–399%, or 400+% of local poverty
level adjusted for family size), and census region (South,
Midwest, West, and Northeast). Race and ethnicity were
categorized as non-Hispanic white, non-Hispanic black, His-
panic, or other, using responses to two questions about race
(white,black,orother)andethnicity(Hispanicornon-Hispanic).
Presence of other medical problems including asthma,
diabetes, and hypertension, was also determined by self-report
of diagnoses. Finally, measures of preventive counseling and
regular healthcare access were adapted from three questions:
“Has a doctor or other health professional ever advised you
to...[exercise more]”; “...[eat fewer high fat or high cholesterol
foods]”; and “About how long has it been since your blood
pressure was checked by a doctor, nurse or other health
professional?” A dichotomous variable (blood pressure
checked within the last year) was created from the answer to
the last of these questions. Year of participation (2000, 2001,
or 2002) did not signiﬁcantly predict aspirin use (P = .50) and
is not included in the analysis.
Statistical Analysis
All demographic, socioeconomic, and clinical characteristics
were compared by gender using X
2 tests for categorical variables.
Logistic regression was used to estimate unadjusted and
adjusted odds ratios for aspirin use. Because effect estimates
were not appreciably altered by the inclusion of the 3
indicators of preventive counseling and health care access,
these variables were removed from the ﬁnal multiple logistic
regression model. This allowed 9 participants who lacked data
for these three variables to be included in the ﬁnal adjusted
analyses. Age was included as both a continuous and categor-
ical (<65, 65–74, and >74 years old) variable. As results were
similar, only results based on age as a categorical variable are
presented. Because MEPS lacks other measures of clinical
appropriateness of aspirin use to validate self-reported contra-
indications, we conducted adjusted analyses for both the full
cohort and the subgroup excluding those reporting a contra-
indication to aspirin.
All two-way interactions with gender were analyzed. A
statistically signiﬁcant two-way interaction was found only
between type of insurance coverage and the effect of gender on
aspirin use (P < .001). The analysis was stratiﬁed accordingly
by insurance coverage. Because previous studies have sug-
gested that younger women may be especially likely to receive
less intensive care after an MI,
21 and because Medicare
eligibility modiﬁes the distinction between private and public
insurance for adults 65 or older, the adjusted analysis was
further stratiﬁed by a dichotomous age variable (<65 and
≥65 years old). A three-way interaction assessed between
gender, insurance status, and this age indicator was signiﬁ-
cant (P < .05). Only 3 participants, 65 years or older, were
uninsured, so results from this group are not reported.
All analyses were conducted with SAS 9.01 (SAS Institute,
Cary, NC) and SUDAAN release 8.0 (Research Triangle Insti-
tute, Research Triangle Park, NC) statistical software to
account for the complex survey design.
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The 2000–2002 MEPS included 25,486 participants, 40 years of
age or older, 1,938 (7.6%) of whom reported either a previous MI
(1303, 5.1%) or CHD alone (635, 2.5%). Of those, 69 (3.6%) were
excluded from the analysis because of missing data. There were
no statistically signiﬁcant observed differences between those
includedandthoseexcludedbecauseofmissingdata(allP >. 1 0 ) .
Overall, 1,869 participants were included in the analysis.
Findings from descriptive comparisons by gender are sum-
marized by Table 1. The prevalence of regular aspirin use was
70.5% in the study cohort, and 84.0% among those without a
contraindication to taking aspirin. In both unadjusted and
adjusted comparisons, women were signiﬁcantly less likely
than men to take aspirin (62.4% vs 75.6%, P < .001, adjusted
OR = 0.62, 95% CI, 0.48–0.79) as shown in Table 2. This
difference persisted when the analysis was limited to the
84.4% of participants without reported contraindications to
aspirin (79.8% vs 86.4%, p = .002, adjusted OR = 0.68, 95%
CI, 0.48–0.97), but the absolute unadjusted gender difference
narrowed from 13.2% to 6.6%. Among those without reported
contraindications, both older and younger participants were
signiﬁcantly less likely to take aspirin than adults age 65–74;
Hispanic adults were less likely than non-Hispanic whites to
be regular aspirin users; and participants who reported a
previous myocardial infarction or hypertension were more
likely to take aspirin regularly. Also notable was a strong
stepwise relationship between higher income and greater
aspirin use.
Participants who reported that a health care provider had
advised them to eat a healthier diet were more likely to take
aspirin (75.0% vs 59.9%, P < .001; adjusted OR = 1.42, 95% CI,
1.06–1.90), as were those counseled to exercise more (74.9% vs
58.0% P <.001; adjusted OR = 1.72, 95% CI, 1.27–2.33), or
whose health care provider had checked their blood pressure in
the past year (70.9% vs 54.6%, P =. 0 4 ;a d j u s t e dO R=2 . 0 3 ,9 5 %
CI, 0.99–4.14). However, including these variables in the regres-
sion model did notappreciably alter estimates, and there were no
signiﬁcant two-way interactions involving these covariates.
Differences in aspirin use between women and men were
greatest among those with private health insurance (p <.001
for a gender-insurance status interaction) (Table 3). Among
those with private insurance, women reported aspirin use less
frequently than men. In contrast, women and men with public
insurance reported aspirin use with similar frequency after
adjusting for confounding characteristics. Compared to a
similar prevalence of aspirin use among women with private
(62.5%) and public coverage (61.8%), men with private cover-
age reported regular aspirin use with greater frequency
(79.0%) than men with public insurance (70.7%). Results for
the uninsured were difﬁcult to interpret because of small sample
size(n=87), and therefore,are not reported. Inclusionofthe three
variables reﬂecting regular preventive care did not diminish this
variation in gender differences by insurance status.
As shown in Figure 1, gender differences in aspirin use were
greater among younger adults (P = .04 for gender–age interac-
tion) when age was dichotomized as younger than 65 versus 65
or older. The modifying effect of insurance status on gender
differences in aspirin use signiﬁcantly differed by age (P = .047
for three-way gender–insurance–age interaction). The differ-
ence in aspirin use reported by privately insured men and
women was more pronounced for those under 65 (59.3% vs
82.5%, P < .001, adjusted OR = 0.29, 95% CI, 0.17–0.48), than
for older participants (63.0% vs 76.2%, P = .002, adjusted
OR = 0.62, 95% CI, 0.41–0.95). In contrast, gender differences
in aspirin use among publicly insured participants were not
signiﬁcant for either age group.
Table 1. Descriptive Statistics by Gender
a
Men Percentage
(%)
Women Percentage
(%)
P
value
b
NN
Total 1,098 771
Age, years
<65 464 43.0 253 30.0 <0.001
65–74 335 29.8 213 28.6
>75 299 27.3 305 41.4
Race/ethnicity
Non-
Hispanic
White
849 84.9 529 79.6 <0.001
Non-
Hispanic
Black
114 6.9 150 13.0
Hispanic 105 5.2 71 4.2
Other 30 3.1 21 3.2
Insurance
Private 686 65.6 373 54.0 <0.001
Public 361 30.5 362 42.4
Uninsured 51 3.9 36 3.6
Percent of federal poverty level
>400% 398 38.7 145 21.8 <0.001
200–399% 333 31.5 181 25.5
125–199% 166 15.4 169 23.0
0–124% 201 14.5 276 29.7
Education level
<HS
education
359 27.9 362 42.9 <0.001
High
school
graduate
325 32.2 255 34.7
>HS
education
414 40.0 154 22.4
Census region
Northeast 174 17.4 127 18.9 0.17
Midwest 254 22.5 190 26.0
South 475 42.2 334 39.3
West 195 17.9 120 15.7
Diabetes
mellitus
301 25.8 272 32.4 0.01
Asthma 111 9.5 161 19.3 <0.001
Prior
Myocardial
Infarction
759 69.5 498 64.9 0.04
Hypertension 768 69.5 612 77.6 0.001
Advised to
exercise
more
c
807 72.7 509 65.7 0.003
Advised to
restrict
high
fat foods
c
852 76.7 554 71.4 0.05
Blood
pressure
checked in
past year
c
1,060 96.5 762 98.8 0.01
aUnweighted sample sizes are presented, but percentages were calcu-
lated using provided analytic weights. Because of rounding, percentages
may not total 100.
bSignificance tests were performed with a X
2 test and were adjusted for
survey design.
cNine participants were excluded from analysis of at least one of the
three variables reflecting health care access because of missing data.
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Status
N Unadjusted
Percentage
(%)
Unadjusted
OR (95% CI)
a
Adjusted
OR
b (95% CI)
All participants
Women 771 62.4 0.54 (0.42–0.68) 0.62 (0.48–0.79)
Men 1,098 75.6
Private insurance
Women 361 61.8 0.43 (0.32–0.59) 0.48 (0.35–0.67)
Men 686 79.0
Public insurance
Women 362 62.5 0.69 (0.48–1.00) 0.74 (0.50–1.11)
Men 361 70.7
Prevalence of aspirin use for men and women, by insurance status, in the
complete study cohort. Univariate and multivariate odds ratios (±95%
confidence intervals) for aspirin use are presented, with men as the
referent group. Results for uninsured participants are not presented
because of the small sample size (n=87).
aOR=odds ratio, CI=confidence interval.
bThe adjusted multivariate model included percent of federal poverty
level, education level, race/ethnicity, age, diabetes mellitus, asthma,
prior myocardial infarction, hypertension, and census region. All results
have been adjusted for the complex design of the survey and analytic
weights.
Figure 1. Gender differences in regular aspirin use stratified by age
and health insurance status, adjusted model*. Odds ratios for
aspirin use in the complete cohort by gender, stratified by
insurance status (men are the referent group). Results for uninsured
participants are not presented because of small sample sizes (n=
84 and n=3 for those <65 and ≥65 years old, respectively).
*The adjusted multivariate model included gender, percent of
federal poverty level, education level, race/ethnicity, diabetes
mellitus, asthma, prior myocardial infarction, hypertension, and
census region. Results have been adjusted for the complex design
of the survey and analytic weights.
†OR = odds ratio, CI = confidence interval.
Table 2. Regular Aspirin Use by Socioeconomic and Clinical Characteristics
Characteristics All Participants All Participants Participants without
contraindication to aspirin
Unadjusted Adjusted
a Adjusted
Percentage (%) OR (95% CI)
b OR (95% CI)
Gender Women 62.4 0.62 (0.48–0.79) 0.68 (0.48–0.97)
Men 75.6 1.00 1.00
Age, years <65 71.4 0.91 (0.67–1.24) 0.57 (0.37–0.86)
65–74 74.3 1.00 1.00
>75 65.9 0.74 (0.54–1.01) 0.58 (0.38–0.88)
Race/ethnicity Non-Hispanic Black 67.3 0.82 (0.58–1.18) 0.66 (0.41–1.07)
Hispanic 63.8 0.85 (0.55–1.32) 0.56 (0.33–0.95)
Other 56.1 0.52 (0.29–0.92) 0.30 (0.15–0.58)
Non-Hispanic White 71.9 1.00 1.00
Insurance Uninsured 61.3 0.72 (0.41–1.28) 0.55 (0.29–1.05)
Public 66.8 0.97 (0.73–1.28) 0.96 (0.64–1.42)
Private 73.1 1.00 1.00
Percent of federal poverty level >400% 76.5 1.80 (1.24–2.62) 2.85 (1.68–4.86)
200%-399% 74.4 1.70 (1.19–2.43) 1.94 (1.21–3.12)
125%-199% 66.2 1.31 (0.91–1.88) 1.60 (0.98–2.61)
0-124% 59.0 1.00 1.00
Education level <High school education 67.4 0.93 (0.67–1.29) 1.04 (0.67–1.62)
High school graduate 68.9 0.82 (0.60–1.12) 0.82 (0.55–1.23)
>High school education 75.1 1.00 1.00
Census region Northeast 73.9 1.40 (0.91–2.15) 1.41 (0.81–2.43)
Midwest 71.5 1.24 (0.83–1.85) 1.27 (0.76–2.10)
South 69.5 1.08 (0.74–1.58) 1.41 (0.88–2.26)
West 67.6 1.00 1.00
Diabetes mellitus Yes 72.1 1.15 (0.87–1.52) 1.45 (0.97–2.16)
No 69.8 1.00 1.00
Asthma Yes 61.2 0.72 (0.52–1.00) 0.78 (0.52–1.18)
No 71.9 1.00 1.00
Prior Myocardial Infarction Yes 71.3 1.16 (0.91–1.50) 1.38 (1.00–1.91)
No 68.6 1.00 1.00
Hypertension Yes 72.1 1.50 (1.16–1.95) 2.08 (1.48–2.93)
No 66.1 1.00 1.00
aThe adjusted multivariate model included gender, insurance status, percent of federal poverty level, education level, race/ethnicity, age, diabetes
mellitus, asthma, prior myocardial infarction, hypertension, and census region. All results have been adjusted for the complex design of the survey and
analytic weights.
bOR=odds ratio, CI=confidence interval.
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tion to aspirin use. Those with asthma reported a greater pre-
valence of aspirin contraindications (21.6% vs 14.7%, P = .02).
Older participants tended to be more likely to report a contra-
indication, although this ﬁnding was not statistically signiﬁcant
(12.6% for <65, 16.6% for 65–74, 18.2% for >74 years old,
P = .08). Women were more likely than men to report a
contraindication (20.5% vs 12.5%, P <.001). This was not
attributable to the age difference between genders. Both women
under 65 years old (19.4% vs 9.6%, P = .005) and those 65 years
or older (21.0% vs 14.7%, P = .01) reported medical contra-
indications more often than men with CHD. The higher
prevalence of asthma among women did not explain the
difference, either. While aspirin contraindications were equally
common for women and men with asthma (22.5% vs 20.5%,
P = .77), women had a higher prevalence of contraindications
(20.1% vs 11.6%, P < .001) among those without asthma. No
other covariates were signiﬁcantly associated with aspirin
contraindications.
Approximately half (52.8%) of participants not taking aspirin
reported a medical contraindication to its use. This ﬁgure was
similar for women and men (54.6% vs 51.0%, P = .45) and both
genders were equally likely to attribute a reported contraindi-
cation to ‘stomach problems’ (33.2% vs 28.1%, P = .38).
DISCUSSION
In this nationally representative study, we found that women
with CHD were signiﬁcantly less likely than men to take aspirin
regularly despite its clear indication. Our ﬁndings suggest that
gender differences previously demonstrated in the treatment of
acute coronary syndromes are also present in the chronic
management of CHD and are signiﬁcant at a population level.
Extrapolation from ﬁndings of previous studies to the United
States population is limited because of the speciﬁc populations
studied and the methods used to assess aspirin use. Our study,
therefore, offers more robust national estimates than studies
that were limited to prescription data, hospital or ambulatory
care of patients, localized geographic regions, or particular
health systems.
7,12,14,15,17–19,21,22
The gender difference in aspirin use remained signiﬁcant
after adjustment for numerous patient characteristics and self-
reported contraindications. Our ﬁndings are, therefore, sugges-
tive of an underlying disparity in the quality of care received by
men and women with CHD. Underuse of aspirin would put
women with CHD at an increased risk of preventable cardio-
vascular events and death. In conjunction with dissimilar acute
treatment and possible sex-related biological differences, this
gender difference in aspirin use for secondary prevention may
help to explain why younger women have poorer outcomes than
men in the ﬁrst few years after an MI.
21,29–32
While characterization of factors contributing to this poten-
tial disparity remains an area for future research, we did ﬁnd
that gender differences in aspirin use were most pronounced
among younger men and women with private health insurance
coverage and that women were more likely to report contra-
indications to aspirin use.
The high rate of aspirin use among non-elderly privately
insured men may be attributable to unmeasured characteris-
tics of working-age men, to gender differences in insurance
beneﬁts, or to features of private health plans such as manda-
tory reporting on standardized performance measures that may
augment secondary prevention in the ambulatory care of men
with CHD. Alternatively, men are more likely to receive ambu-
latory specialty cardiology care after an MI,
33 and private plans
may facilitate such referrals with greater ease and frequency.
A higher prevalence, real or perceived, of adverse effects or
contraindications to aspirin among women could also explain
our ﬁndings.
35,36 Unexpectedly, women were more likely than
men to report contraindications to aspirin use, and limiting the
analysis to those without a contraindication to aspirin use
narrowed the absolute gender gap. Gender was a stronger
predictor of reported contraindications than age. This higher
prevalence of contraindications to aspirin among women is
puzzling. There is no clear gender difference in the prevalence of
peptic ulcer disease or in mortality secondary to its complica-
tions.
37,38 Aspirin use increases the riskof bleeding similarly for
both men and women.
3,4,39,40 Women were more likely to report
asthma, which can constitute a contraindication to aspirin
use,
41,42 but even women without asthma were more likely to
report a contraindication than their male counterparts. Other
adverse effects such as easy bruising, hematuria, and epistaxis
rarely prevent aspirin use.
43,44
Gender differences in aspirin use could also be explained by
uncertainty and related biases among treating physicians. For
example, providers may generalize the unclear efﬁcacy of
aspirin in primary prevention for women at low risk of vascular
events to women with known CHD.
2–4,34
This study has several limitations. The low response rate for
this survey (65%) may be attributable to the long duration of
the survey or to the restriction of participants to the previous
year’s National Health Interview Survey (NHIS) sample (there is
only a 75–80% initial response of these participants to the
MEPS survey). Our ﬁndings could represent a differential
response by gender or aspirin use. Sample weights are
designed to account for, but cannot guarantee the absence
of, nonresponse bias.
Data were ascertained by self-report and our results could
potentially be explained by reporting biases, such as over-
reporting of CHD among women or aspirin use among men.
While some data suggest that women may be less accurate in
reporting a history of MI or cardiac disease,
45 other studies
have found no such difference or have reported higher
accuracy among women.
46,47 No signiﬁcant gender differences
have been demonstrated in studies of the accuracy of self-
reports of other chronic diseases.
48–51
Although the breadth of data in MEPS allowed for adjust-
ment for many patient characteristics, we were unable to
independently assess the clinical appropriateness of aspirin
use, medication adherence, or patient preferences as potential
explanations for our ﬁndings. Speciﬁcally, data on contra-
indications to aspirin use were limited, and the validity of self-
reported contraindications could not be conﬁrmed. As a result,
we could not distinguish real contraindications indicative of
appropriate nonuse from perceived contraindications sugges-
tive of a need for greater patient education.
The contribution of non-adherence to recommended treat-
ment to the observed gender difference could not be studied
with the available data. Several recent papers have found that
women with CHD are less likely to continue evidence-based
therapies prescribed at discharge.
17,52 However, the reasons for
lower persistence were not investigated in these studies, and
poorer adherence is only one potential explanation. Further-
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generally, have demonstrated that gender has no relationship to
adherence.
53–55
In addition, because of the observational cross-sectional
study design, we could not adjust for unobserved differences
between men and women with CHD. There were signiﬁcant
gender differences in many of our measured covariates, and
unmeasured variables could confound or explain our ﬁndings.
Potential unmeasured confounders include the use of other
antiplatelet agents or anticoagulants and health behaviors
such as tobacco use. In addition, we were unable to assess
differences in access and quality of care beyond the receipt of
basic counseling and routine blood pressure monitoring.
Concomitant differences observed in the receipt of specialty
referrals or other recommended elements of care for CHD, for
example, would bolster an argument that our ﬁndings reﬂect a
true gender disparity. Therefore, while our ﬁndings are consis-
tent with the provision of inferior care to women with CHD in
the United States and suggest possible explanations for this
deﬁcit, further research is needed to address the limitations of
this study and to elucidate modiﬁable factors of care to guide
interventions.
Our ﬁndings demonstrate a difference in aspirin use
between women and men with CHD, contribute to growing
evidence of inferior care for women with CHD, suggest an
additional explanation for poorer observed outcomes among
women, and have important policy implications. Women are
not receiving the full beneﬁts of secondary prevention, and as a
result, may be at greater risk for cardiovascular events and
premature death. Thus, distinct beneﬁts to the health of
women with CHD may be realized through greater use of a
very low-cost medication. Although further investigation is
needed to better deﬁne the underlying causes of lower aspirin
use among women, its remedy may require a multifaceted
approach including patient and physician education, en-
hanced measurement and quality improvement initiatives by
providers, health plans, and public insurance programs, and
focused interventions at the point of care.
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